Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 As Single Agent and in Combination with Anti-PD-L1 (atezolizumab) in Adult Patients with Selected Advanced Malignancies

Next Previous
Search
Trial Profile

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 As Single Agent and in Combination with Anti-PD-L1 (atezolizumab) in Adult Patients with Selected Advanced Malignancies

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 21 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alomfilimab (Primary) ; Atezolizumab (Primary)
  • Indications Advanced breast cancer; Carcinoma; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Penile cancer; Renal cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Kymab

    • Most Recent Events

    • 16 Oct 2024 Status changed from active, no longer recruiting to discontinued (Early discontinuation based on strategic sponsor decision not driven by any safety concerns).
    • 19 Sep 2024 Planned End Date changed from 5 Aug 2024 to 27 Sep 2024.
    • 19 Sep 2024 Planned primary completion date changed from 5 Aug 2024 to 27 Sep 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top